GlassScriptPhysician profile
Samantha Sugerman
NPI 1720522048
$2,187.60
in general payments reported to CMS, 2019-2025
23 companies · $637 in 2025
The $637 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $334 · 2023: $293 · 2024: $819 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,614 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,614.02 |
| Education | $134.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $445.75 | 2022-2024 | Xywav |
| Inspire Medical Systems, INC. | $430.47 | 2023-2024 | Inspire |
| Harmony Biosciences LLC | $231.28 | 2023-2024 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $139.09 | 2024 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $138.68 | 2025 | Uptravi, Opsumit |
| Insmed, INC. | $113.41 | 2025 | Arikayce, Brinsupri |
| Axsome Therapeutics, INC. | $101.33 | 2023-2024 | Sunosi |
| United Therapeutics Corporation | $94.72 | 2024-2025 | Tyvaso, Remodulin |
| Takeda Pharmaceuticals U.S.A., INC. | $81.27 | 2021-2025 | Glassia |
| Astrazeneca Pharmaceuticals LP | $67.35 | 2021-2025 | Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.74 | 2021-2025 | Jascayd |
| Bayer Healthcare Pharmaceuticals INC. | $39.92 | 2021-2025 | |
| Verona Pharma, INC. | $38.22 | 2025 | Ohtuvayre |
| Baxter Healthcare | $24.90 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Viatris Specialty LLC | $24.20 | 2025 | Yupelri |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $24.06 | 2025 | Vest Therapy Und |
| Liquidia Technologies, INC. | $21.70 | 2025 | Yutrepia |
| Genzyme Corporation | $19.44 | 2022 | |
| Merck Sharp & Dohme LLC | $19.15 | 2025 | Winrevair |
| Regeneron Healthcare Solutions, INC. | $18.49 | 2021 | |
| Mallinckrodt Hospital Products INC. | $17.12 | 2025 | Acthar |
| Hikma Pharmaceuticals USA | $16.04 | 2025 | Ryaltris |
| Idorsia Pharmaceuticals US INC | $15.27 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Sugerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.